Ipamorelin: the "selective" GH secretagogue, from Novo Nordisk's lab to postoperative ileus

An unexpected finding at Novo Nordisk

By the late 1990s, GH-releasing peptides (GHRPs) had already shown that the pituitary could be stimulated through a pathway other than GHRH¹²; their story, and that of the receptor that led to the discovery of ghrelin, is told in GHRPs and ghrelin. The problem was that first-generation GHRPs also raised ACTH and cortisol. A chemistry program at Novo Nordisk in Denmark looked for a cleaner molecule and found ipamorelin: a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) obtained by removing the central Ala-Trp dipeptide of GHRP-1¹. The compound's data sheet is at Ipamorelin.

In rat pituitary cells, ipamorelin released GH with potency and efficacy similar to GHRP-6 (EC50 of 1.3 vs 2.2 nmol/L). Antagonist studies confirmed that it acts through the same receptor as the GHRPs, now known as the ghrelin receptor (GHS-R1a)¹; its natural ligand, ghrelin, was isolated from the stomach in 1999¹³.

What "selective" means

The finding that named the molecule came from conscious swine. None of the secretagogues tested changed FSH, LH, prolactin or TSH. But GHRP-6 and GHRP-2 raised ACTH and cortisol, whereas ipamorelin did not raise them to levels significantly different from those seen with GHRH. The authors described the finding as surprising, and the lack of effect held at doses more than 200 times the ED50 for GH release¹.

That selectivity is ipamorelin's main theoretical advantage over other members of the class: stimulating the somatotropic axis without activating the stress axis at the same time. Its scope should be stated precisely: it is an animal finding, with maximal GH efficacy similar to GHRP-6 in swine (65 vs 74 ng/mL)¹.

In humans: one GH pulse and a short half-life

Human pharmacokinetics were described in a dose-escalation study using 15-minute intravenous infusions at five levels (4.21 to 140.45 nmol/kg), with eight healthy men per level. Parameters were dose-proportional, with a terminal half-life of 2 hours, clearance of 0.078 L/h/kg and a volume of distribution of 0.22 L/kg². Each administration produced a single episode of GH release, peaking at 0.67 hours and declining exponentially to negligible concentrations, at every dose. Between-subject variability was larger for the GH response than for pharmacokinetics². The pattern is pulsatile, not a sustained rise like that of the long-acting analogs compared in CJC-1295, ipamorelin and MK-677.

Bone and body composition in the lab

In adult female rats treated for 15 days, ipamorelin dose-dependently increased the longitudinal growth rate of the tibia from 42 to 52 µm/day (P < 0.0001), as well as body-weight gain; it did not change total IGF-I or serum bone-turnover markers³. In a 12-week research protocol using subcutaneous minipumps, ipamorelin and GHRP-6 increased bone mineral content measured by DXA. Detailed analysis showed that the increase was due to larger bones; volumetric mineral density did not change, nor did mineral content corrected for body weight⁴. In rats given a glucocorticoid for three months, simultaneous ipamorelin counteracted the loss of muscle strength and the drop in bone formation¹⁴.

Body composition adds a rarely cited nuance. In mice, ipamorelin increased fat-pad weight relative to body weight, in both GH-intact and GH-deficient animals; in GH-intact mice the secretagogues, unlike GH, increased leptin and food intake. The authors concluded that secretagogues increase body fat through GH-independent mechanisms that may include increased feeding⁵. In other words, the effect on the ghrelin receptor is not limited to GH release.

Why it was tested in postoperative ileus

The ghrelin receptor is not only in the pituitary. Its stimulation has promotility effects in the upper and lower gastrointestinal tract⁶, and that was the clinical bet: ipamorelin was developed, sponsored by Helsinn Therapeutics, for postoperative ileus, a common complication after bowel surgery¹¹.

The preclinical data were encouraging. In rats undergoing laparotomy and intestinal manipulation, a single intravenous dose of ipamorelin shortened the time to first bowel movement, and repeated dosing increased fecal output, food intake and weight gain⁷. In the same model, surgery left 78% of a meal in the stomach of control animals versus 52% with ipamorelin (44% in non-operated animals), and the molecule reversed the loss of gastric muscle contractility through a cholinergic, ghrelin-receptor-mediated mechanism⁸.

What the trial measured and why it was not enough

The phase 2 trial was multicenter, double-blind and placebo-controlled, in adults undergoing open or laparoscopic small- or large-bowel resection. They received intravenous infusions of ipamorelin 0.03 mg/kg or placebo twice daily, from postoperative day 1 to day 7 or discharge. The key endpoint was time from first dose to tolerance of a standardized solid meal⁶.

A total of 117 patients were enrolled, 114 of whom made up the safety and analysis populations. Median time to first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p = 0.15): a difference of about seven hours in the drug's favor, but not statistically significant. There were no significant differences in key or secondary endpoints. Adverse events occurred in 87.5% with ipamorelin and 94.8% with placebo, and the authors concluded the drug was well tolerated. They themselves noted as a limitation that the study was small and enrolled patients with a broad range of conditions⁶.

The result was not unique to ipamorelin. Ulimorelin, another ghrelin-receptor agonist, was tested in two phase 3 trials of 332 and 330 patients after bowel resection, and it also failed to beat placebo on the primary or secondary endpoints⁹. Postoperative ileus proved a difficult target for the whole class.

Where the evidence ends

Ipamorelin has no published human trials on body composition, muscle recovery or aging; its clinical development focused on ileus, and the bone and growth effects come from rats³⁴⁶. Selectivity for ACTH and cortisol was shown in animals, not in repeated-dose human trials¹.

In September 2023, the FDA added it to its list of bulk substances that may present significant safety risks in compounding, under category 2 of the 503B policy. It cited a possible immunogenicity risk from aggregation or impurities, and the complexity of characterizing a peptide with unnatural amino acids. It also wrote: "A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility", and that "FDA has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration"¹⁰. The FDA entry does not identify the study or detail the cause of that death; the published abstract of the phase 2 trial reports fewer adverse events with ipamorelin than with placebo⁶¹⁰. In sport, ipamorelin is named among the GH secretagogues in class S2 of the WADA Prohibited List in force since January 1, 2026¹⁵, and anti-doping laboratories have already described its urinary metabolites¹⁶.